Compare iShares MSCI South Korea ETF (EWY) vs Eli Lilly And Co (LLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI South Korea ETF vs Eli Lilly And Co — how do they compare? iShares MSCI South Korea ETF trades at $177.22 (market cap $26.25B), while Eli Lilly And Co trades at $1,179.27 (market cap $1.04T). The key difference: Eli Lilly And Co is far larger — about 39.6× iShares MSCI South Korea ETF's market cap, and Eli Lilly And Co pays a 0.59% dividend while iShares MSCI South Korea ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI South Korea ETF for 47 Days and Eli Lilly And Co for 93 Days on average.
| EWY | LLY | |
|---|---|---|
Market Cap | $26.25B | $1.04T |
Volume | 19,056,075 | 3,064,878 |
Sector | Broad Market / Factor | Health |
52-Week High | $219.20 | $1.28K |
52-Week Low | $80.72 | $799.57 |
Typical Hold Time | 47 Days | 93 Days |
Enterprise Value | — | $1.09T |
Dividend Yield | — | 0.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWY is trading at $176.33, down 4.02% amid bearish technical signals, with moving averages indicating selling pressure. The ETF faces headwinds from rising US yields and oil prices impacting South Korean tech stocks, though RSI levels suggest potential oversold conditions. Recent volatility reflects sensitivity to AI sector dynamics and global macroeconomic factors.
Outlook remains cautious due to concentrated exposure to semiconductor giants Samsung and SK Hynix, creating dependency on memory cycle strength. Investment opportunity exists if AI demand sustains earnings growth, but risks include Fed policy impacts and geopolitical tensions. Governance reforms and deleveraging provide fundamental support amid market turbulence.
Eli Lilly (LLY) trades at $1,169.93, down 1.58% on the day, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The company demonstrates exceptional profitability with 83.4% gross margins and 33.53% net income margins, supported by dominant positioning in weight-loss and diabetes treatments. Recent clinical trial successes for next-generation drugs and expanded FDA approvals reinforce growth prospects.
LLY presents compelling growth potential with analyst consensus target of $1,350 representing 15% upside, though elevated valuations (P/E 39.26) and increasing competition in obesity drugs pose risks. Strong institutional support (73% buy ratings) and positive pipeline developments support continued momentum, but investors should monitor execution risks and market saturation concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI South Korea ETF
EWY tracks the MSCI Korea 25/50 Index, offering targeted exposure to large and mid-cap companies in South Korea. It is structurally centered on the global technology supply chain, industrials, and financial services, serving as a liquid tool for investors seeking a single-country view of this advanced, innovation-led economy.
Read more on EWY →About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →
